{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12D+Mutation", "query": { "condition": "KRAS G12D Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12D+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T13:27:19.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "TSN1611", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyligand Pharmaceuticals (Suzhou) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 440, "start_date": "2024-04-29", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385925" }, { "nct_id": "NCT06218914", "title": "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Colorectal Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Endometrial Cancer", "Solid Tumor, Adult", "KRAS G12D" ], "interventions": [ { "name": "NT-112: Autologous, engineered T Cells targeting KRAS G12D", "type": "BIOLOGICAL" }, { "name": "AZD0240: Autologous, engineered T Cells targeting KRAS G12D", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2024-03-22", "completion_date": "2043-11-18", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 18, "location_summary": "Duarte, California • Los Angeles, California • Newport Beach, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06218914" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT06208124", "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor (Phase 1)", "Pancreas Adenocarcinoma", "Non-small Cell Lung Cancer", "Malignant Melanoma (Cutaneous)" ], "interventions": [ { "name": "IMM-6-415", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208124" }, { "nct_id": "NCT07535112", "title": "A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Colorectal Adenocarcinoma" ], "interventions": [ { "name": "BAY 3771249", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2026-04-07", "completion_date": "2030-07-09", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Duarte, California • San Diego, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07535112" }, { "nct_id": "NCT06445062", "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "CRC", "Pancreatic Ductal Adenocarcinoma", "PDAC", "Gastrointestinal Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RMC-6236", "type": "DRUG" }, { "name": "mFOLFOX6 regimen", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "mFOLFIRINOX regimen", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "RMC-9805", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1130, "start_date": "2024-05-24", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 32, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445062" }, { "nct_id": "NCT07456046", "title": "A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS P.G12D" ], "interventions": [ { "name": "D3S-003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D3 Bio (Wuxi) Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-05-29", "completion_date": "2028-01-11", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07456046" }, { "nct_id": "NCT07023731", "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12D Mutation", "Advanced Solid Cancer" ], "interventions": [ { "name": "ARV-806", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2025-05-29", "completion_date": "2029-04-02", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07023731" }, { "nct_id": "NCT07409272", "title": "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Setidegrasib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "liposomal irinotecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 614, "start_date": "2026-02-17", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 28, "location_summary": "Fort Smith, Arkansas • Fullerton, California • Newport Beach, California + 23 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Edgewood", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07409272" }, { "nct_id": "NCT06428500", "title": "QTX3046 in Patients With KRAS G12D Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "QTX3046", "type": "DRUG" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Quanta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-05-30", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-06-25T13:27:19.117Z", "location_count": 5, "location_summary": "Grand Rapids, Michigan • Durham, North Carolina • Houston, Texas + 2 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428500" } ] }